New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer, according to results from the I-SPY 2 trial presented at the American Association for Cancer Research 2016 Annual Meeting.

 Oncology Nurse Advisor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.